Posts Tagged Company news

Q&A: Kairos – Data Analytics and Reporting Solution

Kairos Q&A Data Analytics and Reporting Tool

Q&A: Kairos – Data Analytics and Reporting Solution

Kairos, Data Analytics and Reporting solution for PharmacovigilanceLast year, Arithmos, a provider of innovative IT solutions with a specific focus on the Life Sciences, announced a partnership agreement with E-project, a consulting and system integration company. Together they have brought to the market Kairos, a unique Data Analytics and Reporting solution for pharmacovigilance.

Kairos gives Life Science companies full visibility of their safety data with real-time reports and dashboards, easily ensures regulatory compliance and creates value from the advanced analysis of their safety data.

We have talked to Silvia Gabanti, Arithmos’ Managing Director, to learn more about this new solution.

How can Kairos improve the pharmacovigilance processes and ease the life of the pharmacovigilance team?

First of all, Kairos allows to produce PSUR/PBRER and other safety reports, automatically, in a simple and error-free manner. It excludes the factor of human error.

Secondly, it allows to optimize the performance of the pharmacovigilance department by creating reports to measure KPIs.

Thirdly, it removes the silos between Pharmacovigilance and Regulatory and Clinical departments supporting the data reconciliation in the most effective way.

Silvia Gabanti Managing Director ArithmosCan other departments use Kairos?

Absolutely, and this makes Kairos unique. It helps to make sense of data regardless of its origin. Now Life Science companies gather enormous amounts of data from different sources, like EDCs and safety systems, and mostly use it to ensure compliance. However, data is much more than this.

Data analysis allows to optimize the processes while reducing the team’s effort and the gap between operational units. This helps to make faster and safer decision and improves the business efficiency. Life Science companies can grow business and act proactively, not only reactively.

Although Kairos was born as a pharmacovigilance reporting and data analytics solution, it can also be used horizontally across the company. Departments from Clinical to Marketing can use it to analyse their data, create reports, and share them easily.

Kairos allows you to break down the silos between the departments.

What makes Kairos a unique solution on the market?

Kairos is the result of a synergy between teams with a decade of experience in business intelligence, data analytics, pharmacovigilance, and Life Sciences in general. It is more than just a piece of technology. Kairos includes the solution itself, consultancy, report building, and fine tuning.

Such a combination makes Kairos a powerful tool that is dispensed with low license and maintenance costs.

How can you describe Kairos’ price model?

It is scalable. You start with the minimum investment with the licenses and configuration. If you would like to add new reports, or extend Kairos to other departments, you can easily do it.

Can Kairos be customised?

Yes, absolutely. The whole system is customisable. The first thing we do is understand our clients business needs and type of reporting required. Then we can customize Kairos based on these expectations.

The next step is to give the clients detailed training. We want them to be completely independent and able to change the format, design or data, themselves, to fit their organisation.

How does Kairos fit the bigger Arithmos goals?

We strive to provide 360-degree support, to our clients, on the road to Digital Transformation. Kairos is another step towards this goal.  It allows Arithmos to give more support to the clients.

We also believe in a proactive approach to safety and regulatory compliance. Harnessing the power of data that Kairos contributes to it.

Last, but not the least, we preach efficiency in operations and processes. Introduction of a tool that can operate horizontally and not vertically, allows to save on IT investments and optimize the departments’ work by breaking down the silos.

Want to learn more about Kairos? Contact Arithmos now to see the demo of teh solution.

Arithmos and E-project Launch Kairos, Data Analytics and Reporting Solution for Pharmacovigilance

Kairos, Data Analytics and Reporting solution for Pharmacovigilance

Arithmos and E-project Launch Kairos, Data Analytics and Reporting Solution for Pharmacovigilance

Verona, Italy, May 26th, 2020 – Arithmos, a provider of innovative IT solutions for Life Sciences, together with its partner E-project, a consulting and system integration company, announced the launch of Kairos, innovative Data Analytics and Reporting Solution for Pharmacovigilance.

Kairos gives Life Sciences companies full visibility of their safety data with real-time reports and dashboards, easily ensures regulatory compliance and creates value from the advanced analysis of their safety data.

Kairos, Data Analytics and Reporting solution for PharmacovigilanceBorn as a platform for the pharmacovigilance department, Kairos can also serve as a horizontal solution that fosters collaboration between departments and gives a company a bigger picture of its data. The innovative solution helps Life Sciences companies make faster and more robust decisions based on the data analysis and visualisation, safeguarding patient’s health more efficiently.

The capabilities of Kairos include:

  • Minimised risks as clear data visualisation makes complex pharmacovigilance data easier to grasp and act on
  • Improved decision making, as data can be easily combined, loaded, and visualised
  • Reduced investments in reporting across the business, as the same tool can be adopted by multiple departments

Features:

  • System agnostic – can be connected to any data source
  • Flexible reporting system – creation and fine tuning of any reports
  • Visual – the solution gives clear visual representation of the data in multiple formats

“We have been providing pharmacovigilance technology for 10 years and we know the most common pains of pharmacovigilance teams. Limited reporting capability is one of them and Kairos solves it by offering a whole range of advanced reports and data visualization dashboards”, said Arithmos Managing Director Silvia Gabanti. “We also believe in lean operations and processes, so we wanted to introduce a solution that can be versatile, and be used across the departments, breaking down the silos between them and allowing more collaboration”.

“In E-project, we are committed to applying our expertise in process engineering and data analysis, to help our customers to harness the power of data. Kairos empowers Life Science organisations to make better decisions daily and become truly data-driven”, said Massimo Businaro, president of E-project.

Contact Arithmos now to see the demo

Arithmos is part of PM Holding, a group of companies operating in the Life Sciences sector. PM Holding provides a complete platform of products and services for end-to-end drug and device development.

E-project is a consulting and system integration company founded in 2001 by professionals from the world of consulting. In its work, E-project addresses issues related to the re-engineering of business processes of customers.

Francesco Danzi
Inside Sales Associate
francesco.danzi@arithmostech.com

Interview with Paolo Morelli: Artificial Intelligence in Clinical Research

AI in Clinical Research

Interview with Paolo Morelli: Artificial Intelligence in Clinical Research

On the 20th of May Paolo Morelli, CEO of Arithmos, joined the Scientific Board of Italian ePharma Day 2020 to discuss the growing role of the new technologies in clinical trials. We have taken this opportunity to talk to him about one of the most debated technologies of the last few years – Artificial Intelligence (AI) – to understand how it is currently used in the industry and what future it has.

There are so many discussions around the AI right now. What are biggest doubts related to it?

There are a number of questions that we are asking ourselves now. Here are just a few examples:

  • Will AI change and automate processes, in clinical research, making it more efficient?
  • Will researchers have to change the way they do their work?
  • Will pharma companies have to reorganize their R&D departments?
  • Will the approach to the training of clinical research personnel change?
  • Will patient privacy be protected?

For sure companies performing clinical trials are more and more interested in AI. They want to have data of higher qualityperform recruitment faster and in general, be more efficient. Also, when it comes to the financial side of the projects, the journey has just begun, and a lot is yet to come.

What does the notion of the AI encompass?

I suggest we start with what is not AI. For example, automation is not AI. Automation is the use of machines that follow a precise program defined by Human Intelligence. The artificial intelligence (AI), sometimes called machine intelligence, is opposite to the Human intelligence (HI). We can define AI as any device that collects information and takes actions that maximize its chance of successfully achieving its goals.

Is AI already used in the clinical trials?

Yes, I can outline two of the biggest areas where it is already in use. The first one is the use of AI over eSource/mSource data to support decision making (for ex: feasibility, communication with the patient) and the second one is the use of AI to reduce data entry and the burden of paper documentation (for ex. eConsent, Regulatory document completion, SDV).

How will the AI use be expanded in the future? Where else we can apply the AI in clinical trials?

For sure AI will allow a continuous communication with the patient, even though the human touch cannot be replaced by technology. I also believe that, at some point, SDV will be fully automated thanks to NLP technologies. With the proper training data set AI will be more successful in detecting data issues than Human Intelligence.

But even if patients and the industry are typically open to the innovative solutions, regulators will have a big role in the spread of the innovation, and can support it by setting up a modern regulatory framework.

Once the AI becomes integral part of the clinical trials industry, what will be the potential benefits for the patients?

AI in Clinical Research

The combination of AI with the scientific content will support a better communication with the patient: eConsent will allow a better understanding of the texts compared to the paper version of the Informed Consent. AI will answer questions that the subjects may have about the study, and the patient will be more informed about how his data is treated. I believe that we will see a bigger presence and influence of the patients in clinical research. It will be important, though, to overcome privacy challenges before introducing technology and informing the patients about the use of all their data.

Do you think the AI will replace the human professionals in clinical trials of the future?

The omnipresence of overly abundant data (both clinical data and project data) can be successfully triaged and managed with the assistance of AI. And yet, it is HI (human intelligence) that is needed to make the final decision from the options offered. Think about our air traffic control system, highly automated, advanced technology, and yet there remains the need for HI to make the final decisions regarding all these simultaneous active flights (projects).

What are the aspects that can determine success of the AI in clinical trials?

There are three main aspects that will determine the success of AI in Clinical Trials. Availability of the technology is not one of them.

One critical aspect is the availability of System Integrators as a bridge between technology and researchers. Their goal will be to understand clinical processes and to shape all this new technology around the clinical trial activities.

The second important aspect will be the ethics, morals, and governance around AI and ML. Regulators and Life Science companies will need to setup a framework before going too far down the road of AI.

And the last thing is data. AI needs data. Accurate data. Lots of it. We need to start collecting organised data and train AI before it can successfully achieve the desired result of making the clinical trials faster, more efficient, and ensuring higher quality.

At Arithmos, did you already start exploring such innovative technologies?

Arithmos, just as other PM Holding companies, has Innovation as its core value, it is at the heart of everything that we do. Looking at the impact of innovative technology on the Life Sciences industry, I believe that investing in this field was the right choice.

At Arithmos we are already supporting our clients with the digital technologies that optimise clinical trial processes and increase patient centricity, ensuring that patients get an active role in the clinical trials.

Would you like to learn how Arithmos can support you in innovating your clinical trials? Contact us by clicking here.

Interested in more materials on Digital Transformation?

Leadership in the Workplace: Angela Weston

International Women's Day

Leadership in the Workplace: Angela Weston

International Women’s Day takes place on March 8th and is an important day in the calendar as it celebrates the social, economic cultural and political achievements of women.  It’s theme this year is “An equal world is an enabled world”. Women today are still striving to close the gap in the workplace, and many seek out networking opportunities by sharing life experiences, philosophies and making new connections.

We have taken the opportunity to talk to Angela Weston, Chief Commercial Officer, PM Holding. Angela has been an influential leader for over 20 years, working with multinational companies in the pharmaceutical, medical device and CRO environments. Angela has an impressive track record of implementing strategies to support global sales, marketing and proposal management.

Do you think there are any differences between how men and women lead?

Yes – I think it is clear in our approaches.  Women tend to be far more critical about their own abilities; instead of being proud of their achievements. There is always a need to strive for excellence and for a woman this can sometimes influence decision-making. Men can come across as more confident in certain situations and this can sometimes work to their advantage and sometime not

A real challenge that remains today is the lack of progress being made across many industries in women climbing the corporate ladder although the glass ceiling is beginning to crack. Women in board room positions fell in 2019, but I see a change afoot.

What are some patterns you’ve noticed over the years about how women develop and manage their careers?

Women have a natural ability to multi-task and prioritise with; family, career, managing social commitments and maintaining outside of work friends and interests. I may be biased, but I think women and multi-tasking are ahead of the curve in this respect. Example: I can run a Global pipeline call, have a glass of wine in hand and be ironing and all at the same time!

What are the biggest challenges you face in management and what keeps you pushing forward?

The biggest challenge is always people management – my role requires me to work cross functionally and with multiple stakeholders. It is important that the work environment is a fun, collaborative but productive one. I always go the extra mile to ensure my team are happy, motivated and well looked after – it’s a big and very important part of my day to day life.

I am always pushing myself and my teams, to exceed in all that they do, being a driven person doesn’t allow me much time to sit still for long – however this approach has always brought success and has allowed me to have choices throughout my career.

Who is one female entrepreneur who you personally admire and why?

Margaret Thatcher, the “Iron Lady” of British politics, she was not afraid to speak her mind and she was driven by her passion and beliefs – she went above and beyond to achieve her goals.

What advice do you have for the next generation of women leaders?

  • Reach for the stars – dream big, you can do anything you want to when you put your mind to it.
  • Have a can-do attitude.
  • Invest time and effort to learn, don’t be afraid to step outside your comfort zone.

What are you most passionate about?

Health, wealth and happiness.

The health and wellbeing of family, friends and colleagues is very important to me. I also have tremendous passion for business and relish new challenges and contributing to the Healthcare Industry gives me a good feeling.

What are your personal values?

Integrity – this has helped me throughout my career, I believe it’s important to be honest and transparent even if the message you sometimes communicate is sometimes a difficult one.

What is your favourite film, website and brand?

  • Top Gun
  • Amazon
  • Channel

Thank you for taking the time to talk to us today.

 

COVID-19: Proactive Action Plan

COVID-19

COVID-19: Proactive Action Plan

Verona, Italy (25 February 2020) – In response to the news from the Italian Authorities, PM Holding Companies (CROS NTArithmos, seQure) are taking the following actions as a precautionary measure in our Italian offices with immediate effect:

STAGE 1: Team Lead Mapping

A complete mapping of staff, internal and external, has been done. For strategic positions and responsibilities, the key backups have been identified to provide continuity and succession of our services.

 STAGE 2: Risk Plan

As a global company many of our employees work from home. However, a contingency plan that allows our Italian staff to work from home during this precautionary period has activated to ensure business as usual across projects.

STAGE 3: Travel Schedule

In response to the Northern Italy lockdown: travel plans in this region for our employees have been rearranged and customers have been advised accordingly, teleconferencing will remain an active channel during this period.

STAGE 4: Continuous Review and Assessment

Our risk plan is under continuous review and assessment. Our primary concern is the health of our employees, customers, partners and suppliers. Please be assured it is business as usual.

If you have any additional concerns, please email us at: info@crosnt.com; info@arithmostech.com; info@sequrelifesciences.com and one of the team will be in touch shortly.

10 years of Arithmos: Interview with Managing Director

10 years Arithmos Silvia Gabanti

10 years Arithmos Silvia Gabanti

10 years of Arithmos: Interview with Managing Director

This year Arithmos is celebrating its 10th anniversary. Founded in 2010, Arithmos was born as an innovative IT solutions provider with a specific focus on the Life Sciences value chain. Since then the company has grown to an international business that offers 360-degree Digital Transformation support to its clients.

We sat down with Silvia Gabanti, Managing Director of Arithmos, to talk about its journey. Silvia joined Arithmos as IT Manager in 2010 during the company’s start-up and growth phase.

Good morning Silvia and congratulations on reaching such an important milestone. Can you tell us how the whole Arithmos adventure started?

It all started with Arithmos sister-company CROS NT – back in 2009 it had a rapidly growing IT department. It soon became clear that the innovative technology support that this IT department was providing to CROS NT could also be offered to other Life Science companies.

However, at the heart of Arithmos lied much more than business logic – there was personal passion for innovation. Arithmos’ CEO, Paolo Morelli, is a person with innovative spirit and love for new technologies. His idea was to change the way Life Sciences companies work by integrating new technologies into their processes and harnessing their advantages.

I would say Arithmos is the result of two important factors – market need and personal passion.

Why did you decide to join the Arithmos project back then?

The answer is really straightforward – I share the innovation spirit of Arithmos CEO! Besides, I was looking for a new and exciting venture and this company clearly had big aspirations!

How working in Arithmos has changed you?

Arithmos is a continuously evolving environment and together with it I grew not only as professional, but also as person. In these 10 years I have worked with an international team and clients that has enabled me to become more open to new ideas and cultures.

What is the part you enjoy about your work the most?

As a Managing Director it gives me great satisfaction to know that our success is down to our extensive expertise and effective collaboration between my talented colleagues and our clients.

You have been with Arithmos through all these 10 years. What were its biggest turning points on this journey?

There were three changes that helped us to arrive where we are now.

First, the decision to move from technology provision to IT service provision. We realised that we need more than a simple product portfolio. We needed a broader vision that encompasses services, consultancy, solutions.

The second moment was the acquisition of Symphony EDC and its further development. Why was it so crucial? It was the start of our software factory, we had an opportunity to create something in close collaboration with the clinical research industry. Working on it together with clinical teams we got a tremendous insight into our target market and their needs. We have realised that we were able to offer high quality solutions based on the market needs at competitive prices. We adopted this approach back then and now it is one of our guiding principles.

The last turning point was the decision to develop pharmacovigilance competencies. It started with the creation of Argus BluePrint, a pre-configured and fully validated solution for fast deployment of Oracle Argus Safety. Pharmacovigilance became one of our core competencies and we keep expanding our pharmacovigilance portfolio. Our continued investment includes Kairos, a Data Analytics and Visualisation system, which will be presented to our clients this year.

Where does Arithmos as a company get inspiration from?

We are the crazy type of people that get inspiration from the challenges – we love taking up complex technology projects that give us an opportunity to innovate.

What is the biggest Arithmos’ strength?

Even though we are a technology company, we do not think only about technology, we look holistically at the client’s needs. We think about people, processes, and how we can combine them with technology in order to provide the best solution.

Let’s talk about future. Where do you want to bring Arithmos in 10 years?

We want Arithmos to grow in response to the evolving technologies. Our core objective is to become the main point of references when it comes to Digital Transformation in Life Sciences across Europe.

Interested in more Arithmos news?

PM Holding Appoints Jan Back as Marketing Director

Jan Back Marketing Director

Jan Back Verona, Italy (30 January 2019) – PM Holding, a group of diverse service providers in the life sciences industry, announces the appointment of Jan Back as Marketing Director to manage marketing across the entire group.

PM Holding consists of specialized service providers in the drug and device development sector including: CROS NT (global, expert biometrics CRO), Arithmos (technology solution provider and system integrator) and seQure Life Sciences (niche provider of vigilance, quality assurance and regulatory services).

Jan brings a wealth of experience in marketing, events and communications to the business. Having previously worked for Cytel, Jan has a tremendous industry experience, including Biometrics, Consulting, Real World Analytics and Data Science.

Angela Weston, CCO of PM Holding, said, “2020 is going to be a very exciting year for the business as we continue to grow our portfolio of companies. Implementing marketing strategies that support the commercial objectives for each company is imperative to our success. Jan’s enthusiasm, innovative ideas and professional approach to any challenge can only enhance our existing industry reputation and brand recognition”.

Jan commented, “I am delighted to have joined PM Holding, I am looking forward to developing the marketing strategies for each business and creating and executing tactical communication plans that will support commercial goals and growth”.

Jan is based in Europe.

Arithmos Celebrating 10th Anniversary

Arithmos Celebrating 10th Anniversary

Verona, Italy, January 1st, 2020 – Arithmos is celebrating its 10th anniversary this month and has a series of publications and events planned to mark the occasion.

During the last decade, Life Sciences companies started focusing on Digital Transformation – a transformation of all the activities, processes and competencies in a way that allows them to harness the advantages of new digital technologies.

Founded in 2010, Arithmos was born as an innovative IT solutions provider with a specific focus on the Life Sciences value chain. Throughout these 10 years, Arithmos has always been at the forefront of innovation. Together with its strategic partners like Oracle, Agatha and E-project, it accompanies its clients on the road of Digital Transformation, helps them to identify their needs and then work together on integrating the right technology to optimize the processes minimizing the change impact.

Arithmos has grown substantially during its time in business and now boasts international team with outstanding expertise, innovative solution portfolio and wide partnership network that allows it to provide 360-degree support to its clients.

Starting from its native Italian market, Arithmos has now evolved into international company with clients across Europe.

Paolo Morelli, CEO, said, “We are extremely proud of Arithmos’ growth both in terms of geographic expansion and business endeavours. In these 10 years we have been working hard to develop the high expertise and partner with other forward-thinking companies to elevate our customers.”

To mark the 10th anniversary, Arithmos has planned the following activities:

  • Testimonials campaign on our Social Media channels: LinkedIn and Twitter;
  • Cake-cutting ceremony at its events 2020;
  • Launch of the special marketing materials for the events.

About Arithmos

Arithmos is part of PM Holding, a group of companies operating in the Life Sciences sector. PM Holding provides a complete platform of products and services for end-to-end drug and device development.

2019: Arithmos Year in Review

Holiday Campaign Arithmos

2019: Arithmos Year in Review

As the year comes to a close, we would like to reflect on our achievements and plans for 2020. What a wonderful year it has been!

Achievements 2019

In 2019, we have:

Direction 2020

We are also excited to share our plans for the future:

  • Create new partnerships with like-minded companies to offer a 360-degree service to our clients;
  • Meet the growing technology market demand in Life Sciences industry;
  • Focus on changing mentality and business processes in industry to foster digitalization;
  • Continue accompanying our clients on a road towards Digital Transformation;

We are looking forward to see what the future holds and wishing everyone happy holiday season!

Warm regards,
The Arithmos team

Arithmos Announces Partnership Agreement with E-project

Arithmos E-project press release

Arithmos partners with E-project

Arithmos Announces Partnership Agreement with E-project

Verona, Italy, November 11th, 2019 – Arithmos, a provider of innovative IT solutions with a specific focus on the Life Sciences value chain, announced that it has signed a partnership agreement with E-project, a consulting and system integration company.

The first result of this collaboration is already underway. The two companies have brought to the market a unique technology solution for pharmacovigilanceData Analytics and Reporting tool. The tool allows Life Sciences companies to easily ensure reporting compliance as well as benefit from the advanced analysis of their safety data.

“Arithmos’ mission is to accompany Life Sciences companies on the Digital Transformation path. We work continuously on enriching our expertise and partnership network in order to give 360-degree support to our clients”, said Arithmos Managing Director Silvia Gabanti. “E-project is a company with advanced technical expertise which is complimentary to the one that Arithmos has. We are lucky to find a partner that shares our vision, our values and our goals.”

“Collaboration with Arithmos is a great opportunity for us to develop and bring new solutions to the market. We implement successful Digital Transformation strategies since 2001. We are happy that Arithmos will accompany us in this journey”, adds President of E-project, Massimo Businaro.

Arithmos is part of PM Holding, a group of companies operating in the Life Sciences sector. PM Holding provides a complete platform of products and services for end-to-end drug and device development.

E-project is a consulting and system integration company founded in 2001 by professionals from the world of consulting. In its work, E-project addresses issues related to the re-engineering of business processes of customers.

Interested in more Arithmos news?

Page 1 of 212

Follow us on Twitter

RESOURCES

NEWS